Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core

PLoS Pathog. 2023 May 18;19(5):e1010981. doi: 10.1371/journal.ppat.1010981. eCollection 2023 May.

Abstract

The spike (S) glycoprotein of SARS CoV-2 is the target of neutralizing antibodies (NAbs) that are crucial for vaccine effectiveness. The S1 subunit binds ACE2 while the S2 subunit mediates virus-cell membrane fusion. S2 is a class I fusion glycoprotein subunit and contains a central coiled coil that acts as a scaffold for the conformational changes associated with fusion function. The coiled coil of S2 is unusual in that the 3-4 repeat of inward-facing positions are mostly occupied by polar residues that mediate few inter-helical contacts in the prefusion trimer. We examined how insertion of bulkier hydrophobic residues (Val, Leu, Ile, Phe) to fill a cavity next to Ala1016 and Ala1020 in the 3-4 repeat affects the stability and antigenicity of S trimers. Substitution of Ala1016 with bulkier hydrophobic residues in the context of a prefusion-stabilized S trimer, S2P-FHA, was associated with increased thermal stability. S glycoprotein membrane fusion function was retained with Ala1016/Ala1020 cavity-filling mutations associated with improved recombinant S2P-FHA thermostability, however 2 mutants, A1016L and A1016V/A1020I, lacked ability to mediate entry of S-HIV-1 pseudoparticles into 293-ACE2 cells. When assessed as immunogens, two thermostable S2P-FHA mutants derived from the ancestral isolate, A1016L (16L) and A1016V/A1020I (VI) elicited neutralizing antibody with 50%-inhibitory dilutions (ID50s) in the range 2,700-5,110 for ancestral and Delta-derived viruses, and 210-1,744 for Omicron BA.1. The antigens elicited antibody specificities directed to the receptor-binding domain (RBD), N-terminal domain (NTD), fusion peptide and stem region of S2. The VI mutation enabled the production of intrinsically stable Omicron BA.1 and Omicron BA.4/5 S2P-FHA-like ectodomain oligomers in the absence of an external trimerization motif (T4 foldon), thus representing an alternative approach for stabilizing oligomeric S glycoprotein vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Antibodies, Neutralizing
  • COVID-19*
  • Humans
  • Severe Acute Respiratory Syndrome*
  • Spike Glycoprotein, Coronavirus

Substances

  • spike protein, SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Angiotensin-Converting Enzyme 2
  • Antibodies, Neutralizing

Grants and funding

This work was funded by the Perpetual Impact Philanthropy Application Program (IPAP2021/0251) (PP and HED), the Burnet Vaccine Initiative (PP and HED), mRNA Victoria Activation Program (mAP) (PP and HED), the Victorian Operational Infrastructure Fund (HED), the Australian Medical Foundation Research Grants (MRF2005760, MRF2001684) and New South Wales Health COVID-19 Research Grants Round 2 (SGT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.